Patents by Inventor Laura L. POLING

Laura L. POLING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPY
    Publication number: 20230355787
    Abstract: This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).
    Type: Application
    Filed: January 26, 2023
    Publication date: November 9, 2023
    Inventors: Rebecca MOSHER, Laura L. POLING, Donald A. BERGSTROM
  • NAPI2B-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF
    Publication number: 20210301031
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: January 20, 2021
    Publication date: September 30, 2021
    Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY
  • COMPOSITIONS AND METHODS FOR PREDICTING RESPONSE TO NAPI2B-TARGETED THERAPY
    Publication number: 20190160181
    Abstract: This disclosure provides reagents and methods of predicting the responsiveness of a patient to NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates).
    Type: Application
    Filed: September 20, 2018
    Publication date: May 30, 2019
    Inventors: Rebecca MOSHER, Laura L. POLING, Donald A. BERGSTROM
  • NaPi2b-targeted Antibody-Drug Conjugates and Methods of Use Thereof
    Publication number: 20170266311
    Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: March 13, 2017
    Publication date: September 21, 2017
    Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY